205259-42-3

Basic information

• Product Name: 4-(7-benzyloxy-6-methoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester
• Synonyms: 4-(7-benzyloxy-6-methoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester
• CAS NO: 205259-42-3
• Molecular Weight: 450.538
• Mol File: 205259-42-3.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 4-(7-benzyloxy-6-methoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(7-benzyloxy-6-methoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester(205259-42-3)
• EPA Substance Registry System: 4-(7-benzyloxy-6-methoxy-4-quinazolinyl)-1-piperazinecarboxylic acid tert-butyl ester(205259-42-3)

Safety Data

• Hazardous Substances Data: 205259-42-3(Hazardous Substances Data)

Upstream product

• 205259-41-2 2-amino-4-benzyloxy-5-methoxybenzoic acid benzyl ester 
• 121-34-6 3-methoxy-4-hydroxybenzoic acid 
• 205259-40-1 4-benzyloxy-5-methoxy-2-nitrobenzoic acid benzyl ester 
• 179688-01-8 7-(benzyloxy)-6-methoxyquinazolin-4(3H)-one 
• 91203-74-6 4-benzyloxy-3-methoxybenzoic acid benzyl ester 
• 162364-72-9 7-benzyloxy-4-chloro-6-methoxyquinazoline 
• 57260-71-6 1-t-Butoxycarbonylpiperazine 

Downstream Products

• 387867-13-2 Tandutinib 

Relevant articles and documents

Potent and Selective Inhibitors of Platelet-Derived Growth Factor Receptor Phosphorylation. 3. Replacement of Quinazoline Moiety and Improvement of Metabolic Polymorphism of 4-[4-(N-Substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline Derivatives

We have previously reported that a series of 4-[4-(N-substituted (thio)carbamoyl)-1-piperazinyl]-6,7-dimethoxyquinazoline derivatives were potent and selective inhibitors of platelet-derived growth factor receptor (PDGFR) phosphorylation and demonstrated several biological effects such as suppression of neointima formation following balloon injury in rat carotid artery by oral administration. Here, we investigated structure-activity relationships of the 6,7-dimethoxyquinazolinyl moiety. In regard to 6,7-dimethoxy groups, ethoxy analogues showed potent activity (IC50 of 16b is 0.04 μM; IC50 of 17a is 0.01 μM) and further extension of the alkyl group reduced activity. Interestingly, methoxyethoxy (IC50 of 16j is 0.02μM; IC50 of 17h is 0.01 μM) and ethoxyethoxy (IC50 of 17j is 0.02 μM) analogues showed the most potent activity, suggesting that the inserted oxygen atom significantly interacts with β-PDGFR. Among tricyclic quinazoline derivatives, the 2-oxoimidazo[4,5-e]quinazoline derivative 21a showed potent activity (IC 50 = 0.10 μM). Regarding replacements of quinazoline by other heterocyclic rings, pyrazolo[3,4-d]pyrimidine (39a, IC50 = 0.17 μM) and quinoline (IC50 of 40a is 0.18 μM; IC50 of 40b is 0.09 μM) derivatives showed potent activity. Isoquinoline and some pyridopyrimidine derivatives were completely inactive; therefore, 1-aza has an important role. Also 7-aza and 8-aza substitution on the parent quinazoline ring has a detrimental effect on the interaction with β-PDGFR. We also demonstrated that the substituents on the quinazoline ring possess major consequences for metabolic polymorphism. Although there existed extensive metabolizers and poor metabolizers in Sprague-Dawley rats administrated 6,7-dimethoxyquinazoline derivatives (1b and 1c), 6-(2-methoxy)ethoxy-7-methoxyquinazoline analogue 16k showed no metabolic polymorphism.

1,3-Diazines with platelet-derived growth factor receptor inhibitory activity.

-